SEC Form SC 13G/A filed by Cytokinetics Incorporated (Amendment)
$CYTK
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/29/2026 | $115.00 | Neutral → Buy | UBS |
| 5/19/2026 | $99.00 | Buy | Citigroup |
| 4/10/2026 | $95.00 | Overweight | Wells Fargo |
| 1/28/2026 | $87.00 | Overweight | Barclays |
| 12/18/2025 | $95.00 | Neutral → Buy | Goldman |
| 7/30/2025 | Mkt Perform | Raymond James | |
| 4/24/2025 | $55.00 | Overweight | Barclays |
| 2/7/2025 | $86.00 | Buy | Citigroup |
SCHEDULE 13G/A - CYTOKINETICS INC (0001061983) (Subject)
S-8 - CYTOKINETICS INC (0001061983) (Filer)
8-K - CYTOKINETICS INC (0001061983) (Filer)
SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that on July 15, 2026 it granted stock options to purchase an aggregate of 21,220 shares of common stock and 14,067 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 10 employees, whose employment commenced in June and July 2026 as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the gr
Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy Company to Host In-Person and Virtual Investor Event to Discuss Results from Late-Breaking Science Presentations SOUTH SAN FRANCISCO, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced three Late Breaking Science abstracts were accepted for presentation at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany, including a Hot Line presentation of the primary results from ACACIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients
SOUTH SAN FRANCISCO, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that on June 15, 2026 it granted stock options to purchase an aggregate of 24,784 shares of common stock and 16,429 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting and 2,242 performance stock units (PSUs) that, if earned, will be settled in shares of common stock upon vesting to 12 employees, whose employment commenced in May and June, 2026, as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSU
UBS upgraded Cytokinetics from Neutral to Buy and set a new price target of $115.00
Citigroup initiated coverage of Cytokinetics with a rating of Buy and set a new price target of $99.00
Wells Fargo initiated coverage of Cytokinetics with a rating of Overweight and set a new price target of $95.00
4 - CYTOKINETICS INC (0001061983) (Issuer)
4 - CYTOKINETICS INC (0001061983) (Issuer)
4 - CYTOKINETICS INC (0001061983) (Issuer)
U.S. Launch of MYQORZO® (aficamten) in Late January Met with Strong Demand; Over 275 HCPs Prescribed MYQORZO to an estimated 680 Patients in Q1 ACACIA-HCM Met Dual Primary Endpoints of KCCQ and Maximal Exercise Performance; Full Results to be Presented at Upcoming Medical Congress MYQORZO Approved by the European Commission for Adults with Symptomatic Obstructive HCM;Supplemental NDA for MAPLE-HCM Accepted for Filing by FDA with PDUFA Date of November 14, 2026 Net Product Revenues for MYQORZO of $4.8 Million for Initial Partial Quarter;~$1.1 Billion in Cash, Cash Equivalents and Investments as of March 31, 2026 SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics,
Trial Met Dual Primary Endpoints of KCCQ and Maximal Exercise Performance With Consistent Positive Findings Across Key Secondary Endpoints Company to Host Conference Call and Webcast Tuesday May 5 at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced positive topline results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (HCM). ACACIA-HCM met both dual primary endpoints, demonstrating statistically significant i
Company to Host Conference Call and Webcast Tuesday May 5 at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced it will report topline results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM) on Tuesday, May 5, 2026. Following the announcement, Cytokinetics will host a conference call at 8:00 AM Eastern Time to discuss the results. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics' website at https://ir.cytokinetics.com or the following link: ACACIA-HCM Topline Re
SC 13G - CYTOKINETICS INC (0001061983) (Subject)
SC 13G/A - CYTOKINETICS INC (0001061983) (Subject)
SC 13G/A - CYTOKINETICS INC (0001061983) (Subject)
"On Track with HCM" Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone's Father, Willie McLaughlin SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the launch of "On Track with HCM," demonstrating the company's long-standing commitment to the HCM community. The campaign features four-time Olympic gold medalist Sydney McLaughlin-Levrone, and her father, three-time all-American track star, Willie McLaughlin, who suffered from the non-obstructive form of hypertrophic cardiomyopathy (HCM) for more than two decades before receiving a heart trans
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025. Mr. Daly brings over 30 years of global biopharmaceutical leadership experience with particular expertise in commercialization to the Company's Board of Directors. "Jim has longstanding expertise leading commercial launches of innovative therapies, coupled with extensive Board experience guiding later-stage, global biopharma companies," said Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "We are pleased to welcome him to our Board and look forward to his contributi
Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential Commercialization SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the appointment of Robert E. Landry to its Board of Directors. Mr. Landry brings over three decades of financial and operational expertise in the pharmaceutical industry, most recently having served as the Chief Financial Officer at Regeneron Pharmaceuticals Inc. for 11 years. "We are pleased to have Bob join our Board as we approach a key shareholder value inflection point for the company and prepare for the potential approval and launch of our first medici